Przejdź do zawartości
Merck

Comparison of oral insulin spray and subcutaneous regular insulin at mealtime in type 1 diabetes.

Diabetes technology & therapeutics (2007-08-21)
Jaime Guevara-Aguirre, Marco Guevara-Aguirre, Jeannette Saavedra, Gerald Bernstein, Arlan L Rosenbloom
ABSTRAKT

The aim of this study was to compare the glucose pharmacodynamics after oral spray insulin (Oral-lyn , Generex Biotechnology, Toronto, ON, Canada) and subcutaneous (sc) injection of regular insulin in 10 subjects with type 1 diabetes mellitus (T1DM). Basal therapy was twice-daily insulin glargine. Preprandial (30 min) regular insulin was given for 3 days, followed by 9 days of Oral-lyn, eight to 12 puffs immediately pre- and postprandially. Adjustments for glycemia were made using standard snacks and additional regular insulin or Oral-lyn. Peripheral glucose measurements were self-monitored in duplicate. Serum concentrations of fructosamine and hemoglobin A1c (HbA1c) were determined at the start and the end of the study period. Average glucose concentrations (in mmol/L) for the 3-day regular insulin and 9-day Oral-lyn periods, respectively, were: pre-breakfast (B), 5.06 and 3.89; 1-h post-B, 8.39 and 7.67; post-B, 6.00 and 6.33; pre-lunch (L), 5.50 and 4.72; 1-h post-L, 7.83 and 7.89; 2-h post-L, 5.89 and 6.33; pre-dinner (D), 5.61 and 5.17; 1-h post-D, 7.22 and 7.83; and 2-h post-D, 6.11 and 6.67. Areas under the curve for both treatments were not significantly different (P = 0.6875). Fructosamine (mean +/- SD, 338.7 +/- 77.4 micromol/L and 321.7 +/- 63.4 micromol/L), and HbA1c (mean +/- SD, 7.5 +/- 1.5% and 7.2 +/- 1.2%) did not change significantly. Regular insulin and Oral-lyn had similar glucodynamic effects in subjects with T1DM receiving twice-daily insulin analogue as baseline therapy. Intensive monitoring and timely corrections with additional snacks, additional sc regular insulin, or Oral-lyn puffs resulted in appropriate glycemic control as assessed by individual daily glycemic responses and, especially, normal preprandial glycemia. Protein glycation decreased, but not significantly.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Dimethylamine solution, 2.0 M in methanol
Sigma-Aldrich
Glycerol, FCC, FG
Sigma-Aldrich
4-Heptanone, ≥97%, FG
Sigma-Aldrich
Butyl alcohol, natural, ≥99.5%, FCC, FG
Sigma-Aldrich
4-Heptanone, 98%
Sigma-Aldrich
1-Methyl-L-histidine, ≥98.0% (TLC)
Sigma-Aldrich
(R)-3-Hydroxybutyric acid, ≥98.0% (T)
Sigma-Aldrich
Dimethylamine solution, purum, 33% in absolute ethanol (~5.6 M)
Sigma-Aldrich
Dimethylamine solution, 40 wt. % in H2O
Sigma-Aldrich
Methylglyoxal solution, technical, ~40% in H2O
Sigma-Aldrich
Glycerol, ≥99.5%
Sigma-Aldrich
Glycerol, Molecular Biology, ≥99.0%
Sigma-Aldrich
Glycerol, BioXtra, ≥99% (GC)
Sigma-Aldrich
Estriol, meets USP testing specifications
Sigma-Aldrich
L-Carnitine inner salt, synthetic, ≥98%
Sigma-Aldrich
Estriol, ≥97%
Sigma-Aldrich
3-Methyl-L-histidine
Sigma-Aldrich
Glycerin, meets USP testing specifications
Sigma-Aldrich
Methylglyoxal solution, ~40% in H2O
Sigma-Aldrich
Glycerol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Levocarnitine, European Pharmacopoeia (EP) Reference Standard
Supelco
4-Heptanone, analytical standard
Sigma-Aldrich
Glycerol, tested according to Ph. Eur., anhydrous
Sigma-Aldrich
Dimethylamine solution, 2.0 M in THF
Sigma-Aldrich
Glycerol, BioUltra, Molecular Biology, anhydrous, ≥99.5% (GC)
Supelco
Estriol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Glycerol, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
Glycerol, ACS reagent, ≥99.5%
Supelco
Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Acetone, ≥99%, FCC, FG